Algernon Pharmaceuticals Inc.
Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on advancing its lead compounds for non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough.
Algernon Pharmaceuticals Inc. (AGN)
Le 14 février/February 2019
Breathtec Biomedical Inc. (BTH) has announced a name and symbol change to Algernon Pharmaceuticals Inc. (AGN).
Shares will begin trading under the new name and symbol on February 19, 2019.